AstraZeneca's Forxiga Gets Nod In Japan For Type I Diabetes
Zacks Investment Research | Mar 27, 2019 10:43PM ET
AstraZeneca plc. (NYSE:AZN) announced that the Japanese regulatory authority has granted marketing approval to its SGLT2 inhibitor Forxiga for a new indication — as an oral adjunct treatment to insulin in adults with type-Idiabetes.
With this approval from the Japanese Ministry of Health, Labour and Welfare (MHLW), Forxigacan now be prescribed to type-Idiabetespatients whose glucose levels are not adequately controlled with insulin alone. The approval is based on data from the phase III DEPICT study and a special study conducted in Japanese patients.
Data from the study showed that both the 5mg and 10mg doses of Forxiga led to significant and clinically-meaningful reductions from baseline in average blood glucose levels HbA1c (primary endpoint), weight and total daily insulin dose (secondary endpoints) at 24 weeks.
Please note that Forxiga was approved for type I diabetes in Europe last week and is under review in the United States for the same indication with a decision expected in the second half of 2019. Forxiga is known by the name of Farxiga in United States. Farxiga/Forxiga is already approved as both monotherapy and combination therapy to improve glycemic control, with additional benefits of weight loss and blood pressure reduction, as an adjunct to diet and exercise in adults with type-II diabetes.
Talking about type-I diabetes drugs, the FDA recently issued a complete response letter to Lexicon Pharmaceuticals, Inc.’s (NASDAQ:LXRX) new drug application seeking approval of its lead pipeline candidate, Zynquista (sotagliflozin). Zynquista is a dual SGLT1 and SGLT2 inhibitor evaluated in combination with insulin for type-I diabetes in adult patients. Lexicon is developing the candidate in collaboration with Sanofi (NASDAQ:SNY) .
AstraZeneca’s stock has rallied 12.3% this year so far, outperforming the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.